Effects of statins on mitochondrial pathways.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic and preclinical literature without systematic review methodology.
PubMed 33511728 · doi:10.1002/jcsm.12654
What was done
This narrative review synthesized literature describing the biological mechanisms by which statins affect mitochondrial function, focusing on pathways linked to statin-associated myopathy and potential connections to conditions such as diabetes and dementia.
What was found
The abstract reports no quantitative metrics or effect estimates. It summarizes mechanistic findings showing that statins reduce coenzyme Q10 levels, inhibit respiratory chain complexes, induce mitochondrial apoptosis, dysregulate calcium metabolism, alter carnitine palmitoyltransferase-2 expression, reduce mitochondrial oxidative phosphorylation, increase oxidative stress, decrease uncoupling protein 3 concentration, and interfere with amyloid-beta metabolism.
Why it matters
It outlines the cellular and molecular pathways through which statin therapy may trigger adverse events, providing biological plausibility for statin-induced muscle symptoms.
Limits
As a narrative review, it lacks systematic search criteria, quality appraisal of included studies, and quantitative synthesis. Clinical incidence rates, risk magnitudes, and patient-level data are not provided in the abstract.
Cited by
- context Cholesterol synthesis pathways produce an essential component of the mitochondrial electron transport system.